Information for Authors

European Journal of Therapeutics (Eur J Ther) is a double-anonymous, peer-reviewed, open access, international publication of the Gaziantep University School of Medicine. The journal is published six issues a year starting in 2024 (February, April, June, August, October, and December).

European Journal of Therapeutics aims to contribute to the international literature by publishing original research, review articles, case reports, letters to the Editor, editorials (only Editors use), special editorial (only Editors use), reply by authors, in memory of (invited by EIC only) and book review (invited by EIC only) in the fields of medical sciences.

The journal's target audience comprises researchers, physicians, and healthcare professionals actively engaged in or deeply interested in all disciplines across the broad spectrum of medical sciences. For details, please refer to the Aim and Scope page.

The European Journal of Therapeutics implements an "Early View" publication model. Manuscripts that have completed the peer review process, received editorial acceptance, and undergone final typesetting are published online with a Digital Object Identifier (DOI) before being assigned to a specific volume and issue. For details, please refer to the Early View Publication Policy page.

The European Journal of Therapeutics maintains a policy of no financial barriers for authors or readers. No fees are charged to authors at any stage of the review and publication process, including submission fees, editorial processing fees, or article processing charges. All manuscripts must be submitted via the online submission system, which is available at www.eurjther.com, where authors can also find the journal guidelines, technical information, and required forms. For details, please refer to the Publication Fee Policy page.

The European Journal of Therapeutics follows the transparency and best practices for scholarly publishing, as identified by the Committee on Publication Ethics (COPE), the Directory of Open Access Journals (DOAJ), the Open Access Scholarly Publishing Association (OASPA), and the World Association of Medical Editors (WAME).

COPE, DOAJ, OASPA, WAME. Principles of Transparency and Best Practice in Scholarly Publishing. Available at: https://doi.org/10.24318/cope.2019.1.12

The European Journal of Therapeutics actively encourages authors to self-archive the final published version of their articles (preprint, accepted manuscript, published article) in institutional repositories, personal websites, or other suitable platforms, further enhancing the accessibility of their research. When sharing or redistributing their work, authors and readers are required to provide accurate citations, including the DOI link to the publisher's definitive version. For details, please refer to the Repository Policy on the Open Access page.

As the European Journal of Therapeutics, our fundamental criteria for every manuscript considered for publication are unwavering originality, superior scientific quality, and significant citation potential. It is imperative that submissions presented for evaluation have not been previously published or presented in any electronic or printed medium. Should a manuscript have been submitted to another journal for assessment and subsequently rejected for publication, it is obligatory to inform our journal; in such instances, the provision of prior reviewer reports will substantially accelerate our evaluation process.

Should the research have been previously presented at a conference or meeting, full details must be disclosed at the point of submission. The title page of the manuscript is required to include the name of the meeting, the date it was convened, and its geographical location (City, Country).

Every manuscript submitted to the European Journal of Therapeutics undergoes a meticulous double-anonymized peer-review process, designed to ensure an unbiased assessment. Within this framework, each submission is rigorously examined by at least two external and independent peer reviewers, all of whom are experts in their respective fields. Furthermore, in cases where manuscripts are submitted by our Editors or members of the Editorial Board, our Editorial Board will specifically engage an external and independent Editor to oversee and manage the evaluation procedures. For details, please refer to the Peer Review Policy page.

The Editor in Chief is the final authority in the decision-making process for all submissions.

An approval of research protocols by the Ethics Committee following international agreements (World Medical Association Declaration of Helsinki "Ethical Principles for Medical Research Involving Human Subjects," amended in October 2024, www.wma.net) is required for experimental, clinical, and drug studies and some case reports. Ethics Committee approval information, including the name of the approving institution, approval date, and approval number, must be declared on the title page and under the Materials and Methods section of the manuscript. Authors should provide the ethics committee reports.

As the European Journal of Therapeutics, we mandate that manuscripts presenting experimental studies with human participants include a definitive statement verifying that comprehensive, written informed consent was secured from all individuals, after a thorough explanation of all procedures involved. Correspondingly, for research conducted on animal subjects, a precise delineation of the measures implemented to preclude pain and mitigate suffering is an essential requirement.

All submissions are screened by similarity detection software (iThenticate by CrossCheck).

The similarity rate limit determined for our journal is 24%. For details, please refer to the Plagiarism page.

In any instance where research misconduct is alleged or suspected – including, but not limited to, plagiarism, manipulative citation practices, or the fabrication/falsification of data – our Editorial Board will meticulously adhere to and implement the comprehensive guidelines established by the Committee on Publication Ethics (COPE). For details, please refer to the Ethical Oversight page.

Each individual listed as an author should fulfill the authorship criteria recommended by the International Committee of Medical Journal Editors (ICMJE - www.icmje.org). Authorship must be based on four key criteria: substantial contributions to the conception or design of the work, or the acquisition, analysis, or interpretation of data; drafting the work or revising it critically for important intellectual content; final approval of the version to be published; and agreement to be accountable for all aspects of the work, ensuring that questions related to its accuracy or integrity are appropriately investigated and resolved. An author must be able to identify which co-authors are responsible for specific parts of the work and should have confidence in the integrity of their co-authors' contributions. All those designated as authors should meet all four criteria for authorship, and all who meet the four criteria should be identified as authors. Those who do not meet all four criteria should be acknowledged on the title page of the manuscript. For details, please refer to the Authorship and Contribution page.

Authors are required to disclose any use of AI-assisted technologies, such as Large Language Models, chatbots, or image generators, during the article preparation process; if AI tools were employed for writing assistance, such as drafting or editing text, this must be explicitly stated in the acknowledgements section on the Title Page. For details, please refer to the Authorship and Artificial Intelligence (AI) tools page.

At the European Journal of Therapeutics, we expect each author to take responsibility for their contributions. Additionally, authors must be able to clearly outline the specific roles and responsibilities of all co-authors regarding other distinct aspects of the work. Furthermore, all contributing authors grant the designated corresponding author the authority to manage the entire publication process.

The European Journal of Therapeutics requires corresponding authors to submit a signed and scanned Copyright Agreement and Acknowledgement of Authorship Form, available for download through www.eurjther.com. Should the Editorial Board suspect a case of "gift authorship," the manuscript will be summarily rejected, without proceeding to an external peer review. When incorporating previously published content, including figures, tables, or any other material in both print and electronic formats, authors are solely responsible for obtaining explicit permission from the respective copyright holder. All legal, financial, and criminal liabilities arising from the unauthorized use of such materials belong entirely to the author (s).

By signing this form, authors agree that the article, if accepted for publication by the European Journal of Therapeutics, will be licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC-BY-NC).

In any instance where research misconduct is alleged or suspected – including, but not limited to, plagiarism, manipulative citation practices, or the fabrication/falsification of data – our Editorial Board will meticulously adhere to and implement the comprehensive guidelines established by the Committee on Publication Ethics (COPE). For all submission types, authors must complete and submit the ICMJE Potential Conflict of Interest Disclosure Form (by all contributing authors). The Editorial Board will follow COPE and ICMJE guidelines in resolving potential conflicts of interest. For details, please refer to the Ethical Oversight page.

The Editorial Board also manages all appeal and complaint cases within the scope of COPE guidelines. Authors or readers should directly contact the editorial office regarding their appeals and complaints. In situations where internal resolution is not possible, an ombudsperson may be assigned to mediate. The Editor-in-Chief holds the final authority in the decision-making process for all appeals and complaints.

The European Journal of Therapeutics requires each submission to be accompanied by a Copyright Agreement and Acknowledgement of Authorship Form (available for download at www.eurjther.com). When using previously published content, including figures, tables, or any other material in both print and electronic formats, authors must obtain permission from the copyright holder. Legal, financial, and criminal liabilities in this regard belong to the author (s). By signing this form, authors agree that the article, if accepted for publication by the European Journal of Therapeutics, will be licensed under a Creative Commons Attribution-Non Commercial 4.0 International License (CC-BY-NC). For details, please refer to the Copyright and Licensing page.

The statements and opinions expressed in articles submitted for publication in the European Journal of Therapeutics belong solely to the authors. The statements and opinions expressed in the published content do not necessarily represent the views of the Editors, the Editorial Board, or the publisher. The ultimate responsibility for the published content rests with the authors.

Before submitting an article, please visit the Writing Rules page.

 

Last Revised on August 2025